Re: Availability of Evidence of Benefits on Overall Survival and Quality of Life of Cancer Drugs Approved by European Medicines Agency: Retrospective Cohort Study of Drug Approvals 2009-2013

Madersbacher Stephan; Kramer Gero

首页> 外文期刊>European urology >Re: Availability of Evidence of Benefits on Overall Survival and Quality of Life of Cancer Drugs Approved by European Medicines Agency: Retrospective Cohort Study of Drug Approvals 2009-2013

【24h】

Re: Availability of Evidence of Benefits on Overall Survival and Quality of Life of Cancer Drugs Approved by European Medicines Agency: Retrospective Cohort Study of Drug Approvals 2009-2013

机译：Re：欧洲药物批准的癌症药物整体生存和生活质量的益处的效益的可用性：审查队列2009-2013的药物认证研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European urology》 |2018年第4期|共2页
作者
Madersbacher Stephan; Kramer Gero;
展开▼
作者单位

Donauspital SMZO Urol Kundratstr 3 A-1220 Vienna Austria;

Donauspital SMZO Urol Kundratstr 3 A-1220 Vienna Austria;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献
中文文献
专利

1. Re: Availability of Evidence of Benefits on Overall Survival and Quality of Life of Cancer Drugs Approved by European Medicines Agency: Retrospective Cohort Study of Drug Approvals 2009-2013 [J] . Madersbacher Stephan, Kramer Gero European urology . 2018,第4期

机译：Re：欧洲药物批准的癌症药物整体生存和生活质量的益处的效益的可用性：审查队列2009-2013的药物认证研究
2. Monitoring evidence on overall survival benefits of anticancer drugs approved by the European Medicines Agency between 2009 and 2015 [J] . Groessmann N., Robausch M., Rosian K., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：2009年至2015年欧洲药物委员会批准的抗癌药物整体生存效益的监测证据
3. Single-Arm Clinical Trials as Pivotal Evidence for Cancer Drug Approval: A Retrospective Cohort Study of Centralized European Marketing Authorizations Between 2010 and 2019 [J] . Tenhunen Olli, Lasch Florian, Schiel Anja, Clinical Pharmacology and Therapeutics . 2020,第3期

机译：单臂临床试验作为癌症药物批准的关键证据：2010年至2019年之间的集中欧洲营销授权的回顾性队列研究
4. Drug effect study on proliferation and survival pathways on cell line-based platform: A stochastic hybrid systems approach [C] . Li Xiangfang, Qian Lijun, Bittner Michael L., 2013 IEEE International Workshop on Genomic Signal Processing and Statistics . 2013

机译：基于细胞系平台的增殖和存活途径的药物作用研究：随机混合系统方法
5. Quasi-experimental study to determine the impact of parallel trade and external reference pricing strategies utilized by the European Union (EU) on the rate of drug approval launches and patient access to U.S. designated fast track drugs and orphan drugs. [D] . King, Josephine G. 2008

机译：一项准实验研究，旨在确定欧盟（EU）使用的平行贸易和外部参考定价策略对药物批准投放率和患者使用美国指定的快速通道药物和孤儿药物的速度的影响。
6. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 [O] . Courtney Davis, Huseyin Naci, Evrim Gurpinar, 2017

机译：欧洲药品管理局批准的抗癌药物总体生存和生活质量受益证据的可得性：药物批准的回顾性队列研究2009-13
7. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency:retrospective cohort study of drug approvals 2009-13 [O] . Davis Courtney, Naci Huseyin, Gurpinar Evrim, 2017

机译：获得欧洲药品管理局批准的关于癌症药物总体生存和生活质量的益处的证据：药物批准的回顾性队列研究2009-13

Re: Availability of Evidence of Benefits on Overall Survival and Quality of Life of Cancer Drugs Approved by European Medicines Agency: Retrospective Cohort Study of Drug Approvals 2009-2013

著录项

相似文献

相关主题

期刊订阅